PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike–ACE2 interaction and protecting lung tissue
Frontiers in Pharmacology · 12.03.2026 · 17
DOI: 10.3389/fphar.2026.1755268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.03.2026. Verfasst von Soheun Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to identify small molecules that inhibit the binding of the SARS-CoV-2 Spike protein to its host receptor, angiotensin-converting enzyme 2 (ACE2), without impairing the enzymatic activity of ACE2. Such inhibitors may support the development of broad-spectrum antivirals and therapeutic strategies for emerging SARS-CoV-2 variants. Through extensive screening using both cell-free and cell-based assays, we identified phenoxy-methylaniline (PoMA) compounds as effective inhibitors of the SARS-CoV-2 Spike-ACE2 interaction. Among these, PoMA-10, featuring trifluoromethoxy and dimethylaniline moieties, exhibited the most potent inhibitory activity while preserving ACE2 enzymatic function. Computational modeling predicted direct binding of PoMA-10 to ACE2, which was corroborated by protein mobility shift assays. This was further substantiated by surface plasmon resonance analysis and molecular dynamics simulations, which confirmed the stable binding of PoMA-10 at an interface-adjacent site on ACE2 and the disruption of SARS-CoV-2 Spike–ACE2 interaction. In Vero cells, PoMA-10 significantly reduced infection by ancestral SARS-CoV-2 and the Delta and Gamma variants. Moreover, PoMA-10 alleviated lung epithelial cell damage and protected against lipopolysaccharide-induced lung injury in vivo . These findings demonstrate that PoMA-10 functions as a dual-action inhibitor blocking viral entry and protecting against lung injury, and highlight its potential as a therapeutic candidate in the management of COVID-19 and related pulmonary complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
- Gradutate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul, Republic of Korea.
- College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
- HITS Inc., Seoul, Republic of Korea.
Zitieren
APA
Lee, S., Yoon, S. J., Lim, J., Oh, J. H., Ryu, J. S., Kim, G., Kang, H., Jo, N., Lee, S., Jang, S., Lee, Y., Park, Y., & Hwang, E. S. (2026). PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike–ACE2 interaction and protecting lung tissue. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1755268
Vancouver
Lee S, Yoon SJ, Lim J, Oh JH, Ryu JS, Kim G, et al. PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike–ACE2 interaction and protecting lung tissue. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1755268
BibTeX
@article{Lee2026,
author = {Lee, Soheun and Yoon, Suh Jin and Lim, Jihae and Oh, Ji Hyun and Ryu, Jae-Sang and Kim, Gahee and Kang, Hyunwoo and Jo, Nayoon and Lee, Sehan and Jang, Sunbok and Lee, Yoonji and Park, Yunjeong and Hwang, Eun Sook},
title = {PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike–ACE2 interaction and protecting lung tissue},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1755268}
}
EUVIMED